ReviewBlood transfusion = Trasfusione del sangue2017
Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies.
Review in Blood transfusion = Trasfusione del sangue, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Emicizumab for the treatment of haemophilia A: a narrative review.Blood transfusion = Trasfusione del sangue · 2019Pooled it
- Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions.American journal of hematology · 2024Review
- Acquired haemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding.Blood transfusion = Trasfusione del sangue · 2022Article
- Recombinant porcine FVIII for bleed treatment in acquired hemophilia A: findings from a single-center, 18-patient cohort.Blood advances · 2020Article
- Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice.Blood advances · 2020Article
- Surgery-associated acquired hemophilia A: a report of 2 cases and review of literature.BMC surgery · 2020Review
- Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia.Blood transfusion = Trasfusione del sangue · 2018Review
- Non-factor replacement therapy for haemophilia: a current update.Blood transfusion = Trasfusione del sangue · 2018Review
- Current and emerging factor VIII replacement products for hemophilia A.Therapeutic advances in hematology · 2017Review
- Acquired haemophilia A with a recalcitrant high-titre factor VIII inhibitor in the setting of interstitial lung disease.BMJ case reports · 2017Article
- Borrowing (once again) from the animal kingdom.Blood transfusion = Trasfusione del sangue · 2017Article
- Acquired factor VIII deficiency: two case reports and a review of literature.Experimental hematology & oncology · 2017Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review focuses on the use of recombinant porcine factor VIII (FVIII) for the treatment of bleeding episodes in patients with severe haemophilia A complicated by inhibitors and in those with acquired haemophilia A due to the onset of anti-FVIII autoantibodies. We present the main characteristics of recombinant porcine factor VIII (FVIII) and provide a summary of the published results of the clinical studies of this novel recombinant FVIII. There is a special emphasis on how the use of recombinant porcine factor VIII (FVIII) is expected to improve the clinical management of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.